HeimMEDP • NASDAQ
add
Medpace Holdings Inc
355,15 $
Eftir lokun(0,00%)0,00
355,15 $
Lokað: 5. feb., 16:01:34 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
346,98 $
Dagbil
345,39 $ - 356,59 $
Árabil
293,37 $ - 459,77 $
Markaðsvirði
11,04 ma. USD
Meðalmagn
216,60 þ.
V/H-hlutf.
31,10
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Tekjur | 533,32 m. | 8,29% |
Rekstrarkostnaður | 249,50 m. | 2,58% |
Nettótekjur | 96,43 m. | 36,68% |
Hagnaðarhlutfall | 18,08 | 26,26% |
Hagnaður á hvern hlut | 3,01 | 34,81% |
EBITDA | 119,79 m. | 30,51% |
Virkt skatthlutfall | 18,82% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Reiðufé og skammtímafjárfestingar | 656,90 m. | 589,97% |
Heildareignir | 2,08 ma. | 40,18% |
Heildarskuldir | 1,20 ma. | 18,39% |
Eigið fé alls | 881,44 m. | — |
Útistandandi hlutabréf | 31,01 m. | — |
Eiginfjárgengi | 12,21 | — |
Arðsemi eigna | 14,02% | — |
Ávöxtun eigin fjár | 28,78% | — |
Peningaflæði
Breyting á handbæru fé
(USD) | sep. 2024info | Breyting á/á |
---|---|---|
Nettótekjur | 96,43 m. | 36,68% |
Handbært fé frá rekstri | 149,08 m. | 30,33% |
Reiðufé frá fjárfestingum | -10,49 m. | -21,06% |
Reiðufé frá fjármögnun | 6,27 m. | 112,73% |
Breyting á handbæru fé | 146,01 m. | 160,40% |
Frjálst peningaflæði | 111,39 m. | 19,66% |
Um
Medpace Holdings, Inc. is a global clinical research organization based in Cincinnati, Ohio, employing approximately 5,400 people. Medpace's mission statement is "to accelerate the global development of safe and effective medical therapeutics" through its high science and disciplined operating approach that leverages local, regulatory, and deep therapeutic expertise across all major areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective. Operating under a full-service model, Medpace provides a therapeutically focused, integrated, global approach to clinical development. The company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
The company started trading stock as a public firm in 2016. Wikipedia
Framkvæmdastjóri
Stofnsett
1992
Höfuðstöðvar
Vefsvæði
Starfsfólk
5.900